Orniject Infusion is a sterile intravenous formulation containing Ornidazole 500 mg combined with Sodium Chloride 0.9% w/v, designed for the treatment of anaerobic bacterial and protozoal infections. Ornidazole, a nitroimidazole derivative, exhibits potent antimicrobial activity by disrupting the DNA synthesis of susceptible organisms, leading to cell death. This infusion is indicated for managing infections such as amoebiasis, giardiasis, trichomoniasis, and various anaerobic bacterial infections including intra-abdominal, gynecological, and dental infections. The presence of Sodium Chloride 0.9% w/v serves as an isotonic vehicle, ensuring compatibility with physiological fluids and minimizing the risk of irritation upon administration. Orniject Infusion is administered intravenously, allowing rapid systemic distribution and effective plasma concentrations, particularly beneficial in severe or complicated infections where oral administration is not feasible. Dosage and duration of therapy should be tailored based on the severity of infection, patient response, and clinical judgment. Caution is advised in patients with hypersensitivity to nitroimidazoles, hepatic impairment, or neurological disorders. Adverse effects may include gastrointestinal disturbances, headache, dizziness, and, rarely, neurotoxicity. Proper aseptic technique must be observed during administration to prevent contamination and ensure patient safety.